JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

Maithili P. Dalvi; Elisabeth D. Martinez

doi:10.1080/23723556.2017.1345352

JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

Maithili P. Dalvi, Elisabeth D. Martinez

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.

Original language	English (US)
Article number	e1345352
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	5
DOIs	https://doi.org/10.1080/23723556.2017.1345352
State	Published - Sep 3 2017

Keywords

Drug resistance
JmjC demethylases
Jumonji inhibitors
KDM
Non-small cell lung cancer
Standard chemotherapy
Taxane-platin

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

Access to Document

10.1080/23723556.2017.1345352

Cite this

@article{13bca9df6c554946a24d6c3a3bae1825,

title = "JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers",

abstract = "Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.",

keywords = "Drug resistance, JmjC demethylases, Jumonji inhibitors, KDM, Non-small cell lung cancer, Standard chemotherapy, Taxane-platin",

author = "Dalvi, {Maithili P.} and Martinez, {Elisabeth D.}",

note = "Funding Information: We acknowledge the contribution and support of all authors and funding sources of the original manuscript.2 E.D.M. acknowledges support from NCI (R01 CA125269), the Friends of the Cancer Center, The Welch Foundation (I-1878), CPRIT (RP160493) and the Department of Defense (W81XWH-16–1–0129). Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2017",

month = sep,

day = "3",

doi = "10.1080/23723556.2017.1345352",

language = "English (US)",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "5",

}

TY - JOUR

T1 - JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

AU - Dalvi, Maithili P.

AU - Martinez, Elisabeth D.

N1 - Funding Information: We acknowledge the contribution and support of all authors and funding sources of the original manuscript.2 E.D.M. acknowledges support from NCI (R01 CA125269), the Friends of the Cancer Center, The Welch Foundation (I-1878), CPRIT (RP160493) and the Department of Defense (W81XWH-16–1–0129). Publisher Copyright: © 2017, © 2017 Taylor & Francis Group, LLC.

PY - 2017/9/3

Y1 - 2017/9/3

N2 - Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.

AB - Resistance to standard taxane-platin chemotherapy and tumor relapse are a major challenge in the treatment of non-small cell lung cancers (NSCLC). Our recent study identified JumonjiC demethylase inhibitors as a highly potent therapeutic strategy for targeting chemoresistant tumors and for preventing the emergence of drug-tolerant clones from taxane-platin treated NSCLCs.

KW - Drug resistance

KW - JmjC demethylases

KW - Jumonji inhibitors

KW - KDM

KW - Non-small cell lung cancer

KW - Standard chemotherapy

KW - Taxane-platin

UR - http://www.scopus.com/inward/record.url?scp=85050742033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050742033&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1345352

DO - 10.1080/23723556.2017.1345352

M3 - Article

C2 - 29057307

AN - SCOPUS:85050742033

SN - 2372-3556

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 5

M1 - e1345352

ER -

JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this